Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD

SAN JOSE, Calif., Feb. 9, 2024 /PRNewswire/ -- Lykos Therapeutics (formerly MAPS Public Benefit Corporation) ( " Lykos " ), a company dedicated to transforming mental healthcare, announced that the U.S. Food and Drug Administration ( " FDA " ) has...

https://www.drugs.com/nda/midomafetamine_240209.html

Source: Drugs.com - New Drug Applications - February 9, 2024 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Men | New Drug Applications | Post Traumatic Stress Disorder